

Resource Summary Report

Generated by SPARC SAWG on Sep 17, 2026

Parkinson's Progression Markers Initiative

RRID:SCR_006431

Type: Tool

Proper Citation

Parkinson's Progression Markers Initiative (RRID:SCR_006431)

Resource Information

URL: <http://www.ppmi-info.org/>

Proper Citation: Parkinson's Progression Markers Initiative (RRID:SCR_006431)

Description: An observational longitudinal clinical study partnership to identify and validate biomarkers of Parkinson disease (PD) progression and provide easy and open web-based access to the comprehensive set of correlated clinical data and biospecimens, information, and biosamples acquired from PD and age and gender matched healthy control subjects to the research community. The data and specimens have been collected in a standardized manner under strict protocols and includes clinical (demographic, motor and non-motor, cognitive and neurobehavioral), imaging (raw and processed MRI, SPECT and DAT), and blood chemistry and hematology subject assessments and biospecimen inventories (serum, plasma, whole blood, CSF, DNA, RNA and urine). All data are de-identified to protect patient privacy. PPMI will be carried out over five years at 21 clinical sites in the United States and Europe and requires the participation of 400 Parkinson's patients and 200 control participants. The PPMI database provides researchers with access to correlated clinical and imaging data, along with annotated biospecimens, all available within an open access system that encourages data sharing (<http://www.ppmi-info.org/access-data-specimens/>). The website hosts an Ongoing Analysis section to keep the scientific community apprised of analyses being completed, in hopes of stimulating collaborations between researchers who are using PPMI data and specimens.

Abbreviations: PPMI

Synonyms: Parkinson's Progression Markers Initiative

Resource Type: biomaterial supply resource, material resource

Keywords: analyze, atlas data, clinical neuroinformatics, computational neuroscience, dicom, imaging genomics, Ioni pipeline, minc, magnetic resonance, pet, spect, dat, image collection, clinical, biological, imaging data, biomarker, imaging, demographic, motor, cognitive, neurobehavioral, hematology, consortium, biosample, sleep, longitudinal, FASEB list

Related Condition: Parkinson's disease, Control

Funding: Michael J. Fox Foundation for Parkinsons Research ;
consortium of industry partners ;
non-profit organizations ;
private individuals

Availability: Open unspecified license, Application required

Resource Name: Parkinson's Progression Markers Initiative

Resource ID: SCR_006431

Alternate IDs: nlx_33115

Alternate URLs: <http://www.nitrc.org/projects/ppmi>

Record Creation Time: 20220129T080236+0000

Record Last Update: 20260912T200236+0000

Ratings and Alerts

No rating or validation information has been found for Parkinson's Progression Markers Initiative.

No alerts have been found for Parkinson's Progression Markers Initiative.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 992 mentions in open access literature.

Listed below are recent publications. The full list is available at [SPARC SAWG](#) .

Kong Z, et al. (2026) AXIN1 Polymorphisms Potentially Modulate Parkinson's Disease Susceptibility: A Cross-Sectional Study in Northern Han Chinese and White Populations. *Neurology and therapy*, 15(1), 325.

Akçimen F, et al. (2026) Long-read sequencing identifies FGF14 repeat expansions in Parkinson's disease. *Brain : a journal of neurology*, 149(5), 1514.

Jin S, et al. (2026) Explainable SHAP- XGBoost with DAT and clinical data for freezing of gait detection in Parkinson disease. *NPJ Parkinson's disease*, 12(1), 42.

McNamara A, et al. (2026) Utility of Baseline Pathological, Neuroimaging and Clinical Markers for Prognosis in Early Parkinson's Disease. *Journal of geriatric psychiatry and neurology*, 39(4), 471.

Rooprai S, et al. (2026) Dancing through time: Cognitive changes over six years of community dance in Parkinson's disease. *Journal of Alzheimer's disease : JAD*, 109(1), 400.

Schumacher J, et al. (2026) Pedunculo-pontine-thalamic cholinergic projections in rapid eye movement sleep behaviour disorder. *NPJ Parkinson's disease*, 12(1).

Jiang GY, et al. (2026) Peripheral Inflammatory Biomarkers in Parkinson's Disease: Clinical Correlations and Stratification. *Cellular and molecular neurobiology*, 46(1).

Helson P, et al. (2026) Pursuit of biomarkers of brain diseases: beyond cohort comparisons. *NPJ digital medicine*, 9(1).

Arnaldi D, et al. (2026) Presynaptic dopaminergic imaging as a neurodegeneration staging biomarker in the alpha-synucleinopathy continuum. *European journal of nuclear medicine and molecular imaging*, 53(7), 4677.

Negida A, et al. (2026) Genetic Associations of Parkinson's Disease Clinical, Pathological, and Data-Driven Subtypes. *Genes*, 17(4).

Merk T, et al. (2026) Invasive neurophysiology and whole brain connectomics for neural decoding in patients with brain implants. *Nature biomedical engineering*, 10(5), 852.

Cui J, et al. (2026) Depression and cognition mediated rapid eye movement sleep behavior disorder to improve the activities of daily living in Parkinson's disease patients. *Frontiers in psychiatry*, 17, 1776297.

Ye Z, et al. (2026) Age at onset of Parkinson's disease modulates the sphingolipid-dopaminergic interplay in autonomic progression. *NPJ Parkinson's disease*, 12(1).

Le Guen Y, et al. (2026) Population-scale burden analysis of rare damaging coding variants identifies novel risk genes for Alzheimer's disease and Parkinson's disease. *medRxiv : the preprint server for health sciences*.

Callén A, et al. (2026) Cortical gyrification deficits in early-stage Parkinson's disease: the importance of bradykinesia. *Brain communications*, 8(2), fcag094.

Brooker SM, et al. (2026) Clinical and Imaging Characteristics of Parkinson's Disease with Negative Alpha-Synuclein Seed Amplification Assay. *Movement disorders : official journal of the Movement Disorder Society*, 41(5), 1114.

Botta R, et al. (2026) APOE, A β 42, and tau differentially impact cognitive decline in Sporadic, GBA1 and LRRK2 Parkinson's disease. *NPJ Parkinson's disease*, 12(1).

Hersonsky D, et al. (2026) Patterns of weariness-related symptoms in Parkinson's disease: impact of disease progression and levodopa treatment. *Clinical parkinsonism & related disorders*, 14, 100442.

Minster N, et al. (2026) Plasma proteomics for Parkinson's disease classification: cross-cohort benchmarking of proteomic, transcriptomic, and multimodal models. *NPJ Parkinson's disease*, 12(1).

Zhou W, et al. (2026) ASL/ALT Ratio in Familial and Sporadic Parkinson's Disease: Insights From Cross-Sectional Logistic Analysis. *Brain and behavior*, 16(4), e71416.